Spanish Ovarian Cancer Research Group

Recent papers from Spanish Ovarian Cancer Research Group

1. TP53 mutations and IGHV in naïve chronic lymphocytic leukemia: retrospective analysis of data from a Spanish collaborative networkInternational Journal of Hematology · 2026
2. Giredestrant plus Everolimus in Advanced Breast CancerNew England Journal of Medicine · 2026
3. Feline Mammary Carcinoma as a Comparative Model of Human Breast Cancer: An Integrative ReviewCancers · 2026
4. Study of post-translational modifications of p53 in multiple myelomaBlood Cancer Journal · 2026
5. 1RO Validation of a prognostic circulating immune protein signature and exploratory dynamic biomarker analyses from the phase III ANITA (ENGOT-Ov41/GEICO 69-O) trial in recurrent ovarian cancer (OC)ESMO Open · 2026
6. Primary Hepatic Masses in Ten Dogs: A Retrospective Surgical Case SeriesVeterinary Sciences · 2026
7. Gut Microbiota Dysbiosis and CIPN: State-of-the-Art Evidence and a Microbiota–Ozone Therapeutic FrameworkCancers · 2026
8. Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancerGynecologic Oncology · 2026
9. Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP InhibitorsJAMA Oncology · 2026
10. Clinical characteristics and survival outcomes in patients with small cell lung cancer in Spain: an analysis of the Thoracic Tumor Registry (2016–2025)Archivos de Bronconeumología · 2026
11. Age-related differences in patient burden in endometrial cancer: Findings from the international EXPRESSION XI/IMPROVE survey.Journal of Clinical Oncology · 2026
12. A phase 1/2 study of REGN5668, a MUC16×CD28 costimulatory bispecific antibody, in combination with other targeted therapies, in patients with recurrent ovarian or endometrial cancer: Trial in progress update.Journal of Clinical Oncology · 2026
13. Group-based versus individualized exercise programs in lung cancer: Results from the randomized crossover LungFit study.Journal of Clinical Oncology · 2026
14. Debio 0123 (zedoresertib), a selective WEE1 inhibitor, in combination with carboplatin in adult patients with platinum-resistant ovarian cancer: Expansion part of the Debio0123-101 phase 1 study.Journal of Clinical Oncology · 2026
15. Shallow whole-genome sequencing genomic instability score across endometrial cancer subtypes.Journal of Clinical Oncology · 2026
16. New Archean and Statherian magmatic records within the Guanhães basement inlier (Araçuaí Orogen, Brazil)Journal of South American Earth Sciences · 2026
17. A randomized, open-label phase II non-inferiority study of niraparib maintenance after 3 versus 6 cycles of platinum-based chemotherapy in patients with completely debulked advanced HRD-positive high-grade ovarian cancer in first-line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62)International Journal of Gynecological Cancer · 2026
18. Health-related quality of life in patients with newly diagnosed advanced ovarian cancer receiving maintenance olaparib plus bevacizumab (PAOLA-1/ENGOT-ov25)JNCI Journal of the National Cancer Institute · 2026
19. Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 studyGynecologic Oncology · 2026
20. Long-Term Young Adult Cancer Survivors with Ovarian Cancer: Subgroup Analysis of the Study “Expression VI–Carolin Meets HANNA–Holistic Analysis of Long-Term Survival with Ovarian Cancer”: The International NOGGO, ENGOT, and GCIG SurveyCancers · 2026